Drug Database
BR

BRAF V600 (THxID BRAF test)

✓ Approved

bioMérieux · BRAF · 辅助诊断

什么是 BRAF V600?

BRAF V600 是一种辅助诊断,由bioMérieux研发。该药已获批,用于治疗相关适应症,给药途径:Others。

药物档案

商品名THxID BRAF test
公司bioMérieux
药物类别辅助诊断
分子靶点BRAF
给药途径Others
状态Approved

作用机制

分子靶点

BRAF V600 作用于 1 个分子靶点:

BRAFB-Raf proto-oncogene, serine/threonine kinase (RAFB1, NS7)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

BRAF V600 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

相关研究文献

PubMedClinical cancer research : an official journal of the American Association for Cancer Research2026-11-17

Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in BRAF-Mutant Melanoma.

Shi Yingxiao Y, Savchenko Alexander A, Brase Jan Christoph JC, Reardon Brendan B et al.

BRAF-targeted therapy (BRAFi/MEKi) and immune checkpoint blockade (anti-PD-1/anti-CTLA-4) have transformed the treatment of BRAF-mutant metastatic melanoma. While most patients who respond to targeted therapy eventually progress, a subset derives durable benefit, and biomarkers to identify this subset would inform optimal treatment selection. We analyzed pre-treatment tumor samples from a clinically annotated cohort of 155 patients with BRAF-mutant metastatic melanoma treated with first-line BRAFi/MEKi and followed for up to five years. Whole-exome sequencing (WES) was performed to derive genomic features, and spatial immunohistochemistry (IHC) characterized the tumor immune microenvironment in a subset of samples. Patients were classified as durable responders (PFS ≥ 24 months) and rapid progressors (PFS < 6 months with progression). A global metric of tumor genomic heterogeneity, rather than individual gene alterations, distinguished these groups. Combining genomic heterogeneity with baseline tumor burden (e.g., lactate dehydrogenase (LDH) or radiographic lesion dimensions), we developed a parsimonious model that predicted durable responders with high precision and specificity. Notably, the analogous population of patients treated instead with immunotherapy were not durable responders, suggesting that the selected predictors of durable responders are targeted therapy specific. Spatial profiling of the immune microenvironment in a subset of pre-treatment biopsies (n = 47) demonstrated that high intratumoral, but not peritumoral, CD8+ T-cell infiltration predicted prolonged survival on BRAF-targeted therapy. These findings highlight the distinct baseline intrinsic and extrinsic features underlying durable response to BRAF-targeted therapy and support their potential implication in guiding treatment selection for patients with BRAF-mutant metastatic melanoma.

PMID 43043005
阅读全文 →
PubMedClinical case reports2026-11-17

Erdheim-Chester Disease Mimicking a Benign Cystic Femoral Lesion: A Diagnostic Pitfall.

Kum Aslı A, Güler Serkan S, Ordu Melike M

Erdheim-Chester disease (ECD) is a rare clonal non-Langerhans cell histiocytosis that usually shows characteristic long-bone involvement and may affect multiple organ systems. Localized skeletal presentations can be diagnostically challenging when imaging resembles a benign bone lesion. A 50-year-old man presented with progressive right distal femoral/knee pain for approximately 6 months, with difficulty bearing weight and walking. Radiographs demonstrated bilateral distal femoral lesions, initially considered possibly benign cystic bone lesions. Because the symptomatic right-sided lesion extended to the articular cartilage surface, curettage and right knee arthroplasty were performed during the same operative session. Histopathology showed fibrosis and numerous lipid-laden foamy histiocytes, prompting investigation for a histiocytic disorder. Lesional cells expressed CD68, Factor XIIIa, and CD163 but not CD1a or S100. VE1 immunohistochemistry showed no BRAF V600E protein expression; molecular testing was not performed. Subsequent 18F-FDG PET/CT identified multiple non-FDG-avid lytic-appearing osseous abnormalities of uncertain etiology, without skeletal or marrow FDG uptake considered significant for malignancy. Systemic treatment was deferred and clinical surveillance continued. This case illustrates a practical diagnostic pitfall: ECD may mimic a benign cystic femoral lesion despite an atypical initial radiological presentation. Recognition of the histopathological pattern, appropriate immunophenotyping, expert review when needed, and systemic staging are important for accurate classification and management.

PMID 43041409
阅读全文 →
PubMedFrontiers in public health2026-11-17

Constructing the Self Data Atlas ontology: a crisp-fuzzy ontology for quality of life representation in children with neurodevelopmental and learning disabilities.

Snead R Sterling RS

The lived experiences of children with neurodevelopmental and learning disabilities are documented through diverse forms of personal data, including identity, medical, mental health, accomplishments, social relationships, financial resources, and personal ecology. However, these records rarely integrate quality of life (QoL) information represented through validated multidimensional frameworks. Building on the gap identified in a companion narrative review, this paper presents a reproducible ontology engineering methodology for representing QoL in children with neurodevelopmental and learning disabilities. The paper presents a design-science methodology for constructing an ontology from the Self Research Institute's Self Data Atlas (SDA), a seven-category taxonomy for organizing longitudinal personal data. Derived from Wieringa's design-science framework, the methodology follows a seven-step protocol comprising: (1) competency-question-based requirements specification; (2) ontology reuse and re-engineering; (3) conceptualization; (4) crisp formalization in OWL 2 DL; (5) fuzzy formalization in Fuzzy OWL 2; (6) alignment with the Common Core Ontology (CCO) as a Basic Formal Ontology (BFO)-conformant mid-level scaffold; and (7) iterative evaluation and refinement. The methodology incorporates two complementary design features. First, it separates factual and classificatory information, including demographics, SNOMED CT diagnostic codes, and clinical observations, represented in classical description logic, from graded and context-dependent QoL concepts, including social inclusion, severity, intensity, and wellbeing, represented using fuzzy datatypes, fuzzy linguistic variables, and graded class membership. Second, it embeds tritemporal reasoning by assigning three temporal qualifiers to each SDA event, state, or information artifact: (1) absolute time, representing when the fact existed in reality; (2) ingestion time, representing when the record entered the system; and (3) assignment time, representing when an interpretative classification was applied. These temporal qualifiers are represented as ontology entities rather than opaque metadata. This tritemporal structure supports longitudinal queries, retrospective recording, and event-history replay. Each stage is illustrated using examples from the seven SDA categories. The paper illustrates how CCO classes provide stable upper-level abstractions for SDA components and interoperability with ICF, SNOMED CT, HL7 FHIR, and the Schalock-Verdugo QoL model. This paper makes a methodological rather than an empirical contribution. It provides a reproducible ontology engineering methodology for future SDA ontology development and related personal-data ontologies.

PMID 43041417
阅读全文 →
PubMedHCA healthcare journal of medicine2026-11-17

Making Diagnostic Uncertainty Visible at Intensive Care Unit Transitions: A Narrative Review of Diagnostic Pause Strategies.

West Raha R, ElHaddad Ahmed A, Baharlo Behrad B, Patel Parind P

Diagnostic error is a significant patient safety issue in critical care. However, it is often difficult to detect during ongoing care. Patients in the Intensive Care Unit (ICU) often have incomplete histories, overlapping symptoms, changing physiology, and concurrent issues. During ICU transitions, patient diagnoses are often reported without clear information on diagnostic confidence, potential alternative diagnoses, pending results, or triggers needing review. This clinical narrative review explored diagnostic uncertainty at ICU transitions, specifically those during ICU-to-ward transfers or unplanned escalations to the ICU. A targeted literature search identified studies of adult ICU diagnostic errors, ICU transition safety, ICU-PAUSE and diagnostic-pause literature, pediatric critical care diagnostic timeouts, and broader diagnostic safety reviews. A narrative approach was selected because the evidence was diverse and not suitable for meta-analysis. The literature indicates that diagnostic discrepancies occur in the ICU, that ICU transfers are high-risk periods for adverse events and communication failures, and that diagnostic-pause tools may help make uncertainty more visible. Although clinical outcome evidence remains limited, the safety rationale is strong. A brief diagnostic pause can help ICU teams make diagnostic uncertainty explicit by asking: What is the working diagnosis? How certain are we? What else could be possible? What is still pending? What should prompt re-evaluation? Who owns the follow-up? Making these points explicit may support safer handovers, clearer follow-up and earlier diagnostic review after ICU transitions.

PMID 43042407
阅读全文 →
PubMedItalian journal of dermatology and venereology2026-11-17

Cutaneous and systemic treatment-related adverse events as prognostic markers in immunotherapy and targeted therapy, with a focus on melanoma.

Crespi Orsola O, Santaniello Umberto U, Rosset François F, Pala Valentina V et al.

Immune checkpoint inhibitors (ICIs) and targeted therapies have transformed the management of advanced malignancies but are associated with characteristic adverse events (AEs), many of which are skin-predominant. Increasing evidence indicates that selected treatment-related AEs, particularly immune-related adverse events (irAEs) and on-target toxicities, may serve as dynamic biomarkers of antitumor activity. This review summarizes current data on the incidence, spectrum, and prognostic significance of irAEs and targeted-therapy AEs, with a specific emphasis on cutaneous events relevant to dermatologists. We highlight the robust association between cutaneous irAEs (cirAEs) - including vitiligo, regression of melanocytic nevi and halo phenomena in melanoma - and improved clinical outcomes. We also examine prognostic data for other cutaneous patterns (lichenoid, psoriasiform, bullous), endocrine and other organ-specific irAEs, and on-target dermatologic toxicities under epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR), and BRAF/MEK inhibition. Finally, we discuss mechanistic hypotheses and practical implications for dermatology practice, stressing the need to balance recognition of toxicity as a favorable biomarker with timely management to avoid treatment interruption.

PMID 43043303
阅读全文 →
PubMedThe Journal of clinical and aesthetic dermatology2026-11-17

Erosion of Clinicopathologic Correlation in the Diagnosis of Pigmented Skin Lesions: Electronic Medical Record Artifacts, Diagnostic Inflation, and Downstream Consequences.

Obagi Sabine S, Cockerell Clay J CJ

To evaluate the clinical utility and diagnostic concordance of the designation "rule out melanoma" (ROM) in dermatopathology requisitions and to assess its potential contribution to diagnostic inflation. An observational analysis was conducted of 13,000 dermatopathology requisition forms submitted between January 1 and July 1, 2025, in which ROM was listed as the primary or sole clinical diagnosis. Concordance between clinical designation and histopathologic diagnosis was assessed. Of 13,000 cases, 1,196 (9.2%) were diagnosed as melanoma (invasive or melanoma in situ). The remaining 11,804 cases (90.8%) represented nonmelanoma diagnoses, most commonly solar lentigo, seborrheic keratosis, melanocytic nevi (including dysplastic nevi), pigmented actinic keratosis, and pigmented basal cell carcinoma. This analysis represents a single-institution observational dataset. The ROM designation demonstrates low positive predictive value and provides limited actionable diagnostic information. These findings suggest that current clinical labeling practices may contribute to reduced diagnostic specificity and broader patterns of diagnostic inflation.

PMID 43042111
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多BRAF V600